Name:
A video summary of the TOPAZ-1 Study PLSP: Durvalumab and Chemotherapy for Advanced Biliary Tract Cancer
Description:
A video summary of the TOPAZ-1 Study PLSP: Durvalumab and Chemotherapy for Advanced Biliary Tract Cancer
Thumbnail URL:
https://cadmoremediastorage.blob.core.windows.net/0fb9b389-7b2a-4ca6-bc25-62641104b962/videoscrubberimages/Scrubber_45.jpg
Duration:
T00H01M51S
Embed URL:
https://stream.cadmore.media/player/0fb9b389-7b2a-4ca6-bc25-62641104b962
Content URL:
https://cadmoreoriginalmedia.blob.core.windows.net/0fb9b389-7b2a-4ca6-bc25-62641104b962/VJBM-2023-0017 TOPAZ-1 Video v0.5 (1).mp4?sv=2019-02-02&sr=c&sig=L4qB%2BZKJgbnYlcT21B8FIgPh0GczBiH%2BddRX0IR%2FleE%3D&st=2025-04-03T20%3A48%3A57Z&se=2025-04-03T22%3A53%3A57Z&sp=r
Upload Date:
2025-04-01T00:00:00.0000000
Transcript:
Language: EN.
Segment:1 Biliary Tract Cancer + How does durvalumab work?.
SPEAKER:
SPEAKER: Biliary tract cancers, or BTCs, include cancers of the gallbladder and bile ducts inside or outside the liver. BTCs are usually diagnosed at advanced stages of disease. Historically, the standard of care for advanced BTC was chemotherapy. Only around 50% of people survive longer than one year after starting treatment with chemotherapy. New treatment options are needed. Durvalumab is a new type of treatment called immunotherapy that helps the immune system fight cancer.
Segment:2 How was the TOPAZ-1 study conducted?.
SPEAKER: The TOPAZ-1 study looked at treatment with durvalumab, or placebo, in combination with chemotherapy for people with advanced BTC.
Segment:3 What were the results of the study?.
SPEAKER: Participants who took durvalumab and chemotherapy were 20% less likely to die compared with those who took placebo and chemotherapy. Additionally, participants who took durvalumab and chemotherapy were 25% less likely to experience their cancer growing, spreading, or getting worse than those who took placebo and chemotherapy.
SPEAKER: Adding durvalumab to chemotherapy did not cause substantially more side effects than chemotherapy alone, and the side effects observed were expected with immunotherapy or chemotherapy. The results of this study support adding durvalumab to chemotherapy as a new initial treatment option for people with advanced BTC. Durvalumab and chemotherapy is now approved for adults with BTC in many countries.
Segment:4 Closing.
SPEAKER: in many countries.
SPEAKER:
